508 related articles for article (PubMed ID: 29702089)
1. Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase.
Lee JH; Baek SY; Jang EJ; Ku SK; Kim KM; Ki SH; Kim CE; Park KI; Kim SC; Kim YW
Chem Biol Interact; 2018 Jun; 289():68-74. PubMed ID: 29702089
[TBL] [Abstract][Full Text] [Related]
2. Cynandione A from Cynanchum wilfordii inhibits hepatic de novo lipogenesis by activating the LKB1/AMPK pathway in HepG2 cells.
Kim S; Yoon YY; Park YW; Whang WK; Park SY; Hwang KW
J Nat Med; 2020 Jan; 74(1):142-152. PubMed ID: 31463669
[TBL] [Abstract][Full Text] [Related]
3. Chronic treatment with the modified Longdan Xiegan Tang attenuates olanzapine-induced fatty liver in rats by regulating hepatic de novo lipogenesis and fatty acid beta-oxidation-associated gene expression mediated by SREBP-1c, PPAR-alpha and AMPK-alpha.
Ren L; Sun D; Zhou X; Yang Y; Huang X; Li Y; Wang C; Li Y
J Ethnopharmacol; 2019 Mar; 232():176-187. PubMed ID: 30590197
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol inhibits LXRα-dependent hepatic lipogenesis through novel antioxidant Sestrin2 gene induction.
Jin SH; Yang JH; Shin BY; Seo K; Shin SM; Cho IJ; Ki SH
Toxicol Appl Pharmacol; 2013 Aug; 271(1):95-105. PubMed ID: 23651738
[TBL] [Abstract][Full Text] [Related]
5. Deoxypodophyllotoxin in Anthriscus sylvestris alleviates fat accumulation in the liver via AMP-activated protein kinase, impeding SREBP-1c signal.
Kim KY; Park KI; Lee SG; Baek SY; Lee EH; Kim SC; Kim SH; Park SG; Yu SN; Oh TW; Kim JH; Kim KJ; Ahn SC; Kim YW
Chem Biol Interact; 2018 Oct; 294():151-157. PubMed ID: 30148990
[TBL] [Abstract][Full Text] [Related]
6. Ursolic Acid, a Novel Liver X Receptor α (LXRα) Antagonist Inhibiting Ligand-Induced Nonalcoholic Fatty Liver and Drug-Induced Lipogenesis.
Lin YN; Wang CCN; Chang HY; Chu FY; Hsu YA; Cheng WK; Ma WC; Chen CJ; Wan L; Lim YP
J Agric Food Chem; 2018 Nov; 66(44):11647-11662. PubMed ID: 30359008
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of SREBP-1c-mediated hepatic steatosis and oxidative stress by sauchinone, an AMPK-activating lignan in Saururus chinensis.
Kim YW; Kim YM; Yang YM; Kim TH; Hwang SJ; Lee JR; Kim SC; Kim SG
Free Radic Biol Med; 2010 Feb; 48(4):567-78. PubMed ID: 20005944
[TBL] [Abstract][Full Text] [Related]
8. Nectandrin B, a lignan isolated from nutmeg, inhibits liver X receptor-α-induced hepatic lipogenesis through AMP-activated protein kinase activation.
Choi du G; Kim EK; Yang JW; Song JS; Kim YM
Pharmazie; 2015 Nov; 70(11):733-9. PubMed ID: 26790190
[TBL] [Abstract][Full Text] [Related]
9. An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK.
Kim TH; Eom JS; Lee CG; Yang YM; Lee YS; Kim SG
Br J Pharmacol; 2013 Apr; 168(7):1647-61. PubMed ID: 23145499
[TBL] [Abstract][Full Text] [Related]
10. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
11. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
Hong Y; Choi SI; Hong E; Kim GH
J Food Sci; 2020 Jul; 85(7):2216-2226. PubMed ID: 32579753
[TBL] [Abstract][Full Text] [Related]
12. Oleanolic Acid Inhibits Liver X Receptor Alpha and Pregnane X Receptor to Attenuate Ligand-Induced Lipogenesis.
Lin YN; Chang HY; Wang CCN; Chu FY; Shen HY; Chen CJ; Lim YP
J Agric Food Chem; 2018 Oct; 66(42):10964-10976. PubMed ID: 30351048
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of gomisin N against hepatic steatosis through AMPK activation.
Yun YR; Kim JH; Kim JH; Jung MH
Biochem Biophys Res Commun; 2017 Jan; 482(4):1095-1101. PubMed ID: 27914812
[TBL] [Abstract][Full Text] [Related]
14. Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice.
Luo L; Fang K; Dan X; Gu M
Lipids Health Dis; 2019 Jan; 18(1):11. PubMed ID: 30621686
[TBL] [Abstract][Full Text] [Related]
15. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
16. Combination of honokiol and magnolol inhibits hepatic steatosis through AMPK-SREBP-1 c pathway.
Lee JH; Jung JY; Jang EJ; Jegal KH; Moon SY; Ku SK; Kang SH; Cho IJ; Park SJ; Lee JR; Zhao RJ; Kim SC; Kim YW
Exp Biol Med (Maywood); 2015 Apr; 240(4):508-18. PubMed ID: 25125496
[TBL] [Abstract][Full Text] [Related]
17. Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes.
Seo MS; Kim JH; Kim HJ; Chang KC; Park SW
Toxicol Appl Pharmacol; 2015 Apr; 284(2):113-24. PubMed ID: 25737164
[TBL] [Abstract][Full Text] [Related]
18. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
19. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase.
Choi YJ; Suh HR; Yoon Y; Lee KJ; Kim DG; Kim S; Lee BH
Arch Pharm Res; 2014; 37(9):1169-76. PubMed ID: 24633463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
